The patient continued to have persistent CLL and in September of 2018 was treated with anti-CD19 chimeric antigen receptor (CAR)-T cell therapy, and by October of 2018 there was no morphologic or immunophenotypic evidence for CLL. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.